Stay updated on PK and Safety of Omalizumab in Healthy Subjects Clinical Trial
Sign up to get notified when there's something new on the PK and Safety of Omalizumab in Healthy Subjects Clinical Trial page.

Latest updates to the PK and Safety of Omalizumab in Healthy Subjects Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe ClinicalTrials.gov record for a completed Phase 1 omalizumab comparison study is displayed, with study details, participant criteria, Australian locations, and pharmacokinetic and safety outcome measures.SummaryDifference47%

- Check17 days agoChange DetectedThe site footer's revision identifier changed from v3.7.2 to v3.8.0, while the study page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check24 days agoChange DetectedA notice about NIH’s terminology transition was added, linking to updates and FAQs and stating that federal agencies are using “Super Intelligence” in place of “Artificial Intelligence.”SummaryDifference1%

- Check31 days agoChange DetectedThe footer revision label changed from v3.7.1 to v3.7.2, while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check38 days agoChange DetectedThe footer revision identifier changes from v3.7.0 to v3.7.1 while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check59 days agoChange DetectedRevision: v3.7.0 is now shown, and a large set of study documents and related items in the Study Documents section were removed. The update changes what materials are readily available for review and verification of the study record.SummaryDifference18%

Stay in the know with updates to PK and Safety of Omalizumab in Healthy Subjects Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PK and Safety of Omalizumab in Healthy Subjects Clinical Trial page.